Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CELZ 
Creative Medical Technology Holdings Inc (CELZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: CELZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.83% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.03M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 5.34 | 52 Weeks Range 1.69 - 6.90 | Updated Date 09/14/2025 |
52 Weeks Range 1.69 - 6.90 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -98656.76% |
Management Effectiveness
Return on Assets (TTM) -49.02% | Return on Equity (TTM) -79.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2487742 | Price to Sales(TTM) 1505.31 |
Enterprise Value 2487742 | Price to Sales(TTM) 1505.31 | ||
Enterprise Value to Revenue 414.62 | Enterprise Value to EBITDA -1.45 | Shares Outstanding 2580530 | Shares Floating 2179724 |
Shares Outstanding 2580530 | Shares Floating 2179724 | ||
Percent Insiders 1.37 | Percent Institutions 8.03 |
Upturn AI SWOT
Creative Medical Technology Holdings Inc
Company Overview
History and Background
Creative Medical Technology Holdings, Inc. (CMT) focuses on biotechnology, specifically in the field of regenerative medicine. Founded in 2011, the company has evolved through research and development of immunotherapies, stem cell therapies, and regenerative medicine solutions.
Core Business Areas
- Immunotherapy: Development of immunotherapies targeting cancer and autoimmune diseases.
- Stem Cell Therapy: Research and development of stem cell-based therapies for various conditions.
- Regenerative Medicine: Developing regenerative medical products for tissue repair and other applications.
Leadership and Structure
The leadership team consists of executives focused on science, medicine and business development. The organizational structure is designed around research, clinical trials, and commercialization efforts.
Top Products and Market Share
Key Offerings
- StemSpineu00ae: StemSpineu00ae is being studied to treat lower back pain, potentially addressing disc regeneration and pain management. This is pre-market and does not have market share yet. Competitors include companies like DiscGenics and Mesoblast which are in similar stages of the clinical trial process.
- ImmCelzu00ae: ImmCelzu00ae is an immunotherapy technology designed to improve the effectiveness of cancer treatments. This is pre-market and does not have market share yet. Competitors include companies that develop adoptive cell therapies, such as Kite Pharma (GILD) and Novartis (NVS).
Market Dynamics
Industry Overview
The regenerative medicine and immunotherapy industries are growing rapidly, driven by advancements in biotechnology and increasing demand for novel therapies.
Positioning
Creative Medical Technology Holdings is positioned as an innovator in regenerative medicine and immunotherapy, particularly in the development of cell-based therapies. It aims to develop and commercialize therapies that address unmet medical needs.
Total Addressable Market (TAM)
The TAM for regenerative medicine and immunotherapies is projected to reach billions of dollars in the coming years. Creative Medical Technology Holdings is targeting specific segments of this market, focusing on cell-based therapies for cancer, autoimmune diseases, and orthopedic conditions.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Strong intellectual property portfolio
- Focus on unmet medical needs
- Experienced scientific team
Weaknesses
- Limited financial resources
- Early stage of development
- Reliance on clinical trial outcomes
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Increased funding for regenerative medicine research
Threats
- Regulatory hurdles
- Competition from established companies
- Failure of clinical trials
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- MESO
- NK
- CRSP
Competitive Landscape
The competitive landscape is characterized by established pharmaceutical and biotechnology companies, as well as emerging players in regenerative medicine and immunotherapy. Creative Medical Technology Holdings differentiates itself through its proprietary technology platforms and focus on cell-based therapies. Due to its early stage of development, CMT has no current market share as the Key Competitors are mainly in clinical trial phases. The market share (%) of the Key Competitors is small because they are not on the market yet.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development activities, patent filings, and the advancement of preclinical and clinical programs.
Future Projections: Future growth is contingent on positive clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates are speculative and dependent on company milestones.
Recent Initiatives: Recent initiatives include clinical trial enrollment for StemSpineu00ae and advancement of ImmCelzu00ae technology.
Summary
Creative Medical Technology Holdings is an early-stage biotechnology company focused on regenerative medicine and immunotherapy. It has promising technology platforms but faces challenges related to funding and clinical trial success. Its success hinges on obtaining positive clinical trial outcomes and establishing strategic partnerships. The company has a strong portfolio but should be cautious to avoid overspending. The company needs to be mindful of its small market capitalization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Publicly Available Information
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on available information and may be subject to change. Investing in biotechnology companies involves significant risks, including the potential for loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Creative Medical Technology Holdings Inc
Exchange NASDAQ | Headquaters Phoenix, AZ, United States | ||
IPO Launch date 2015-11-06 | Co-Founder, Chairman, President & CEO Mr. Timothy Warbington | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.